Apathy Clinical Trial
Official title:
Cognitive and Neural Mechanisms of Multidimensional Apathy in Psychiatric Pathologies
Apathy is defined by quantitative decrease in goal-directed activity in comparison to the person's previous level of functioning. Apathy is a transnosographic symptom, prevalent in many neurological and psychiatric pathologies (specifically in schizophrenia and depression), and almost half of patients suffer from it. It is an important source of burden, affecting both personal and occupational life. Despite its high prevalence and negative consequences, no pharmacological or non-pharmacological treatments exist, the underlying mechanisms of apathy being poorly understood. The main aim of the present study is to advance in our knowledge of cognitive and neural mechanisms of apathy by using a multidimensional model of apathy, distinguishing three forms: executive, emotional and auto-activation/initiative. the investigators hypothesize, independently of the pathology (schizophrenia and depression), the existence of different cognitive deficits underlying each of the 3 subforms of apathy. Indeed, according to the predictions of Levy and Dubois' model (2006), executive disorders underlie the cognitive form of apathy. It may be related to lesions of the dorsolateral prefrontal cortex and the cognitive territory of the basal ganglia. Emotional apathy could be due to motivational disorder. Dysfunctions or lesions in the orbital and medial prefrontal cortex and limbic territories of the basal ganglia may underlie this. Finally, the initiative form, may be a mixed form, with both motivational and executive difficulties. Lesions or dysfunctions may affect both the cognitive and limbic territories of the basal ganglia or the anterior cingulate cortex.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
| Recruiting |
NCT03293537 -
Dementia Associated Apathy.
|
N/A | |
| Terminated |
NCT01825577 -
Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
|
Phase 4 | |
| Withdrawn |
NCT00792662 -
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
|
Phase 4 | |
| Recruiting |
NCT03590327 -
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
|
N/A | |
| Completed |
NCT02190084 -
Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia
|
Phase 4 | |
| Completed |
NCT05808530 -
Cognitive Stimulation Therapy
|
N/A | |
| Completed |
NCT00767091 -
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
|
Phase 3 | |
| Not yet recruiting |
NCT06184165 -
Stratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms Alleviation
|
N/A | |
| Terminated |
NCT02915484 -
Transcranial Direct Current Stimulation (tDCS) in Chronic Post-Stroke Apathy
|
N/A | |
| Recruiting |
NCT01885806 -
Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease
|
Phase 2 | |
| Not yet recruiting |
NCT01765257 -
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
|
Phase 4 | |
| Recruiting |
NCT01689181 -
Apathy in Schizophrenia
|
N/A | |
| Active, not recruiting |
NCT02786667 -
Non Motors Aspects in De Novo Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT01914965 -
Apathy Cure Through Bupropion in Huntington's Disease
|
Phase 2 | |
| Completed |
NCT01117181 -
Apathy in Dementia Methylphenidate Trial (ADMET)
|
Phase 2 | |
| Terminated |
NCT05182151 -
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
|
||
| Completed |
NCT00844090 -
The Role of Apathy in Glycemic Control
|
N/A | |
| Completed |
NCT01172145 -
Treatment of Apathy in Alzheimer's Disease With Modafinil
|
Phase 3 | |
| Completed |
NCT00456820 -
Wellbutrin XL Effects on SSRIs Induced Changes
|
Phase 4 |